Around 47,700 men are diagnosed with prostate cancer in the UK each year, making it the most common cancer in men in the UK. It develops in the prostate, a walnut-sized gland found at the base of the bladder.
Our scientists have uncovered a new marker that’s found on treatment-resistant prostate cancer cells.
Trial finds prostate radiotherapy plus standard treatment improves survival for some men whose prostate cancer has spread, which could help thousands in the UK.
By studying small differences in our DNA, called SNPs, our scientists are showing how these could be used to help prevent cancer in the future.
Questions are being asked of the tests used to diagnose prostate cancer, and how they can be improved. We cover the latest research, including specialist MRI.
With new cancer detection technology on the horizon, ranging from blood tests to wristbands, understanding overdiagnosis is a huge challenge.
Our new research shows that a one-off PSA test doesn’t save lives from prostate cancer.
Physicists in Cambridge are using light and sound to gather information on prostate cancer in mice. This could show doctors how aggressive a tumour is.
Read Alfred’s story of joining the STAMPEDE clinical trial. His is one of the many stories featured in our 2016/17 Annual Review.
Targeted treatment up front improves survival for advanced prostate cancer, and we predict a change in thinking for precision cancer medicine.